We could not find any results for:
Make sure your spelling is correct or try broadening your search.
SASKATOON, Saskatchewan, Nov. 26, 2024 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce the filing on SEDAR+ of its unaudited...
L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - PCRX Canada NewsWire VANCOUVER, BC, le 25 sept. 2024 VANCOUVER, BC, le 25 sept. 2024...
Canadian Investment Regulatory Organization Trade Resumption - PCRX Canada NewsWire VANCOUVER, BC, Sept. 25, 2024 VANCOUVER, BC, Sept. 25, 2024 /CNW/ - Trading resumes in: Company: PharmaCorp Rx...
SASKATOON, Saskatchewan, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that, pursuant to share purchase agreements...
Suspension de la négociation par l'Organisme canadien de réglementation des investissements - PCRX Canada NewsWire VANCOUVER, BC, le 25 sept. 2024 VANCOUVER, BC, le 25 sept. 2024...
Canadian Investment Regulatory Organization Trading Halt - PCRX Canada NewsWire VANCOUVER, BC, Sept. 25, 2024 VANCOUVER, BC, Sept. 25, 2024 /CNW/ - The following issues have been halted by...
SASKATOON, Saskatchewan, Sept. 03, 2024 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that, further to its news release dated...
REGINA, Saskatchewan, Aug. 22, 2024 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has agreed to acquire from two arm’s...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions